Jasper is a biotechnology company focused on developing and commercializing safer, more effective conditioning agents to allow for expanded use of curative therapy with stem cell transplantation and gene therapies. Our lead compound, JSP191, is in clinical development as a conditioning antibody that clears hematopoietic (blood and bone marrow) stem cells from bone marrow in patients undergoing hematopoietic cell transplantation. We plan to expand our pipeline to other novel therapies for immune modulation, graft engineering and cell and gene therapies. Our goal is to make cures possible with hematopoietic cell transplantation and gene therapies for all types of patients, including children and the elderly.
JSP191 is a unique antibody that targets the underlying biology of hematopoietic stem cells to improve the efficacy and safety of the conditioning regimen for hematopoietic stem cell transplantation. A first-in-class humanized monoclonal antibody, JSP191 is in clinical development as a conditioning agent to clear hematopoietic stem cells from bone marrow. JSP191 binds to human CD117, a receptor for stem cell factor (SCF), which is expressed on the surface of hematopoietic stem and progenitor cells. The interaction of SCF and CD117 is required for stem cells to survive. JSP191 blocks SCF from binding to CD117 and disrupts critical survival signals, leading to the depletion of stem cells and creating an empty space in the bone marrow for donor or gene-corrected cells to engraft.
Jasper Therapeutics has assembled an exceptional management team of experienced biopharma industry veterans. With this leadership, we are well positioned to achieve our vision of revolutionizing hematopoietic cell transplantation with safer conditioning regimens.
January 9, 2020
December 9, 2019
December 6, 2019